mosquitoborn
alphaviru
chikungunya
viru
chikv
recent
reemerg
produc
largest
epidem
ever
record
viru
million
case
acut
chronic
rheumat
diseas
current
licens
vaccin
chikv
current
antiinflammatori
drug
treatment
often
inadequ
describ
isol
character
two
human
monoclon
antibodi
chikv
infect
recov
individu
determin
potent
viru
neutral
antibodi
biosensor
antibodi
bind
studi
demonstr
recogn
residu
intact
chikv
vlp
shotgun
mutagenesi
alanin
scan
percent
residu
glycoprotein
chikv
envelop
show
epitop
bound
includ
aminoacid
acidsensit
region
asr
chikv
glycoprotein
asr
critic
rearrang
chikv
fusion
viral
entri
host
cell
predict
prevent
event
occur
use
prophylact
chikv
mous
model
complet
protect
chikv
viremia
arthriti
also
observ
administ
therapeut
hour
postchikv
challeng
gave
protect
pathogen
mous
model
given
target
novel
neutral
epitop
potent
protect
vitro
vivo
like
import
region
futur
antibodi
vaccinebas
intervent
chikv
chikungunya
viru
chikv
mosquitoborn
alphaviru
first
isol
tanzania
caus
sporad
outbreak
predominantli
rheumat
diseas
everi
year
primarili
africa
asia
largest
epidem
chikv
diseas
ever
record
took
place
involv
estim
million
case
first
autochthon
chikv
infect
europ
itali
franc
import
case
also
report
nearli
countri
includ
european
countri
japan
usa
epidem
associ
emerg
new
clade
virus
effici
transmit
aed
albopictu
mosquito
vector
seen
dramat
global
expans
geograph
distribut
chikv
diseas
character
acut
chronic
polyarthritispolyarthralgia
usual
symmetr
often
incapacit
occasion
protract
symptom
fever
rash
myalgia
andor
fatigu
often
also
present
acut
phase
recent
epidem
also
associ
atyp
sever
clinic
form
chikv
diseas
fatal
appear
restrict
young
elderli
patient
comorbid
chikv
virion
contain
three
major
structur
protein
glycosyl
el
envelop
env
protein
embed
viral
membran
nonglycosyl
nucleocapsid
protein
base
similar
alphavirus
mediat
receptor
attach
class
ii
viral
fusion
protein
third
glycoprotein
associ
matur
virion
alphavirus
other
protein
membraneassoci
peptid
creat
cleavag
polyprotein
releas
incorpor
particl
low
level
organ
alphaviru
surfac
glycoprotein
virion
defin
use
cryoelectron
microscopi
cryoem
atom
structur
chikv
glycoprotein
recent
solv
xray
crystallographi
matur
particl
immatur
env
precursor
polyprotein
prior
furin
cleavag
copi
three
glycoprotein
come
togeth
form
protein
coat
icosahedr
symmetri
contain
spike
fold
transport
surfac
function
glycoprotein
reli
correct
interact
consist
three
bsheet
domain
term
ii
iii
contain
three
immunoglobulinlik
domain
b
c
nterminu
complex
domain
b
lie
membran
distal
end
contact
domain
c
closest
viral
membran
domain
center
interact
later
along
domain
ii
along
addit
point
contact
region
contain
intern
fusion
loop
tip
domain
ii
matur
structur
exist
bhairpin
lodg
groov
domain
b
also
play
role
protect
fusion
loop
prematur
exposur
treatment
chikv
rheumat
diseas
usual
involv
nonsteroid
antiinflammatori
drug
nsaid
andor
simpl
analges
provid
relief
often
inadequ
although
number
vaccin
strategi
explor
current
licens
human
vaccin
nevertheless
clear
chikv
neutral
antibodi
infect
human
vaccin
monkey
mediat
protect
prophylact
soon
exposur
polyclon
immunoglobulin
deriv
human
recov
chikv
infect
passiv
transfer
neonat
interferon
ab
receptor
defici
ifnar
mice
protect
anim
chikvinduc
viremia
mortal
purifi
total
igg
monkey
immun
three
time
chikv
viruslikeparticl
vaccin
contain
similarli
protect
ifnar
mice
chikv
viremia
mortal
recent
studi
describ
two
monoclon
antibodi
mab
isol
chikv
infect
individu
mab
specif
neutral
chikv
onyongnyong
viru
onnv
viru
close
relat
chikv
none
alphavirus
test
mab
use
escap
mutant
studi
shown
recogn
key
residu
respect
combin
also
shown
significantli
delay
chikvdriven
lethal
mice
defici
ifnab
ifnc
receptor
matur
b
cell
similarli
group
mousederiv
mab
cluster
close
put
receptorbind
domain
also
found
protect
variou
degre
mous
model
chikv
addit
immunodomin
linear
epitop
nterminu
also
target
protect
antibodi
herein
describ
isol
character
two
human
mab
patient
infect
chikv
recov
also
report
character
antibodi
bind
epitop
use
librari
alanin
scan
mutant
chikv
envelop
cover
residu
chikv
glycoprotein
although
bind
epitop
map
chikv
abl
potent
neutral
chikv
neutral
epitop
bound
map
acidsensit
region
asr
critic
rearrang
chikv
fusion
viral
entri
host
cell
purifi
human
antibodi
use
prophylact
adult
wildtyp
mous
model
chikv
diseas
complet
protect
viremia
arthriti
written
inform
consent
obtain
recov
chik
donor
itali
reunion
franc
collect
compli
relev
human
subject
research
protocol
approv
institut
review
board
univers
bologna
centr
hospitali
universitair
respect
anim
work
conduct
accord
good
anim
practic
nhmrc
australia
approv
qimr
anim
ethic
committe
addit
murin
studi
perform
blood
system
research
institut
approv
institut
anim
care
use
committe
isi
servic
llc
san
carlo
ca
follow
recommend
nation
research
council
institut
laboratori
anim
resourc
publish
guid
care
use
laboratori
anim
chikv
mab
variabl
chain
sequenc
mc
lab
south
san
francisco
ca
mammalian
express
variabl
heavi
vh
light
vl
chain
cdna
synthes
genscript
piscataway
nj
closest
human
germlin
signal
sequenc
ss
vkiii
use
ensur
effici
process
secret
ssvh
cassett
clone
pcagg
mammalian
express
vector
ecorinhei
fragment
upstream
human
heavi
chain
constant
region
ssvl
cassett
clone
ecoribsiwi
fragment
upstream
human
kappa
light
chain
constant
region
chikv
fab
variabl
heavi
light
chain
cdna
bear
human
signal
sequenc
synthes
genscript
cassett
clone
mfeinhei
mfeibsiwi
fragment
upstream
respect
constant
region
describ
chikv
character
acut
chronic
polyarthr
polyarthralgia
debilit
protract
current
fdaapprov
vaccin
specif
antivir
treatment
chikv
thu
identifi
character
human
monoclon
antibodi
direct
chikv
could
util
prophylact
immedi
postexposur
set
patient
deriv
monoclon
antibodi
could
also
provid
use
inform
critic
antigen
epitop
develop
futur
vaccin
biolog
describ
identif
two
monoclon
antibodi
isol
recov
patient
potent
inhibit
chikv
infect
cell
prevent
viremia
arthriti
mous
model
chikv
diseas
epitop
antibodi
includ
aminoacid
residu
key
acidsensit
region
glycoprotein
chikv
rearrang
region
follow
exposur
low
ph
critic
uncov
portion
companion
glycoprotein
requir
success
entri
chikv
cell
hypothes
bind
antibodi
region
stabil
nativ
complex
thu
prevent
rearrang
chikv
wildtyp
envelop
pseudovirion
product
chikv
envelop
pcagg
vector
use
pseudoparticl
prepar
describ
previous
lentivir
pseudotyp
produc
essenti
describ
use
mg
luciferas
report
plasmid
pnlluc
base
mg
plasmid
encod
viral
envelop
virion
concentr
ultracentrifug
concentr
rotor
beckman
sucros
cushion
h
pellet
resuspend
overnight
hbss
alphaviru
envelop
express
rrv
sfv
sinv
use
control
pseudovirion
neutral
assay
chikv
wildtyp
pseudoviru
neutral
assay
hek
cell
plate
cellswel
dmem
hyclon
contain
addit
incub
c
co
overnight
follow
day
serial
dilut
antibodi
viru
preincub
min
ad
hek
cell
spin
infect
perform
min
cell
incub
addit
hour
antibodyviru
mix
remov
aspir
replac
ml
prewarm
fresh
media
cell
incub
hr
sampl
recov
measur
luciferas
activ
cell
lysat
per
manufactur
protocol
promega
chik
wildtyp
viru
product
plaqu
assay
prnt
assay
chikv
obtain
atcc
atcc
strain
origin
isol
serum
patient
east
africa
expand
suckl
mice
replic
compet
chikv
grown
vero
cell
vero
cell
plate
costar
plate
overnight
serial
dilut
viru
stock
ml
incub
cell
hr
one
hour
incub
overlay
agaros
life
technolog
dmem
supplement
fb
ad
cell
incub
hr
subsequ
well
fix
formaldehyd
stain
crystal
violet
methanol
ethanol
plaqu
count
white
background
vero
cell
plate
costar
plate
overnight
serial
dilut
monoclon
antibodi
mix
chik
live
viru
dilut
pfuml
preincub
hour
follow
ml
antibodyviru
mixtur
ad
confluent
vero
cell
monolay
addit
hour
subsequ
viru
remov
overlay
agaros
dmem
supplement
fb
ad
cell
incub
hr
plaqu
stain
count
describ
prnt
titer
calcul
reciproc
serum
dilut
reduct
number
plaqu
compar
neg
control
presenc
media
mab
pbmc
ebv
transform
b
cell
isol
obtain
two
chikv
infect
recov
individu
b
cell
isol
use
miltenyi
mac
switch
memori
b
cell
isol
kit
accord
manufactur
protocol
cell
plate
cell
per
well
ubottom
plate
pbmc
unrel
donor
treat
mitomycin
c
use
feeder
cell
cell
per
well
cell
cultur
rpmi
supplement
fb
iul
roch
mgml
peptid
invivogen
filter
ebv
supernat
dilut
ad
well
incub
one
week
replac
fresh
media
ebv
transform
b
cell
supernat
express
chikv
specif
antibodi
screen
chikv
pseudotyp
neutral
potenti
cell
posit
well
clonal
isol
limit
dilut
follow
expans
clone
immun
fab
phage
display
librari
construct
peripher
blood
donat
three
chikvinfect
individu
three
individu
infect
island
franc
outbreak
peripher
blood
sampl
drawn
year
infect
serum
analyz
presenc
neutral
antibodi
use
chikv
report
viru
pseudotyp
total
rna
prepar
use
trireag
sigma
standard
protocol
rna
convert
cdna
use
super
script
firststrand
synthesi
system
rtpcr
invitrogen
follow
manufactur
instruct
construct
librari
perform
genscript
piscataway
nj
previous
describ
final
librari
transform
ecoli
cell
invitrogen
use
electropor
qualiti
librari
assess
sequenc
analysi
randomli
pick
clone
biosensor
studi
perform
use
fortebio
octet
red
biosensor
system
fortebio
menlo
park
ca
chikv
vlp
load
onto
aminereact
biosensor
tip
use
immobil
human
antibodi
chikv
gift
dendrit
lyon
franc
briefli
tip
activ
minut
mixtur
mm
edc
carbodiimid
hydrochlorid
sigma
st
loui
mo
mm
sulfonh
nhydroxysulfosuccinimid
sigma
st
loui
mo
water
dilut
mgml
mm
sodium
acet
ph
allow
react
minut
tip
deactiv
minut
ethanolamin
sigma
st
loui
mo
brief
rins
chikv
vlp
dilut
mgml
load
minut
follow
minut
stabil
tip
transfer
pb
buffer
supplement
mgml
bsa
pbsb
subsequ
antibodi
bind
studi
prepar
twofold
serial
dilut
start
mgml
plu
buffer
blank
antibodi
associ
measur
minut
follow
minut
dissoci
buffer
nonspecif
bind
assess
use
sensor
tip
without
vlp
data
analysi
perform
use
octet
data
analysi
fortebio
menlo
park
ca
bind
kinet
analyz
use
standard
bind
model
chikv
env
express
construct
strain
ctermin
tag
subject
highthroughput
alanin
scan
mutagenesi
gener
comprehens
mutat
librari
primer
design
mutat
residu
within
region
env
alanin
alanin
codon
mutat
serin
total
chikv
env
mutant
gener
coverag
sequenc
confirm
array
plate
env
mutant
transfect
cell
allow
express
hr
cell
stain
h
human
mab
mgml
mgml
mgml
isol
phage
display
librari
ident
manner
mgml
gift
dendrit
rabbit
polyclon
antibodi
dilut
gift
ibt
bioservic
dilut
ng
sigma
mab
detect
use
mgml
secondari
antibodi
ng
jackson
immunoresearch
laboratori
h
mean
cellular
fluoresc
detect
use
intellicyt
high
throughput
flow
cytomet
htfc
intellicyt
antibodi
reactiv
mutant
env
clone
calcul
rel
wildtyp
env
protein
reactiv
subtract
signal
mocktransfect
control
normal
signal
wildtyp
envtransfect
control
mutat
identifi
critic
epitop
support
reactiv
test
human
mab
support
reactiv
chikv
antibodi
counterscreen
strategi
facilit
exclus
env
mutant
misfold
express
defect
critic
amino
acid
requir
antibodi
bind
visual
chikv
env
crystal
structur
monom
pdb
id
trimer
pdb
id
obtain
epitop
map
femal
mice
week
old
inocul
chikv
describ
previous
briefli
mice
inocul
chikv
log
cell
cultur
infect
dose
ccid
ml
rpmi
supplement
fetal
calf
serum
shallow
subcutan
inject
top
toward
later
side
hind
foot
metatars
region
inject
toward
ankl
mice
n
mice
per
group
inject
pb
ii
purifi
mab
iii
purifi
control
human
mab
mgmous
intraperiton
rout
one
day
day
prior
infect
day
chikv
order
avoid
stimul
nonspecif
immun
respons
may
interfer
chikv
infect
adult
mice
control
antibodi
endotoxin
level
eumg
use
arthriti
monitor
measur
height
width
metatars
area
hind
feet
use
digit
calip
data
present
group
averag
percentag
increas
foot
foot
compar
foot
day
viremia
measur
collect
ml
blood
tail
vein
minicollect
serum
separ
tube
greiner
bioon
gmbh
kremsmunst
austria
tube
spun
min
benchtop
microcentrifug
serum
collect
viral
titer
determin
describ
previous
express
ccid
per
ml
abil
antibodi
protect
lethal
effect
chikv
infect
evalu
murin
model
previous
describ
anim
experi
perform
approv
institut
anim
care
use
committe
isi
servic
llc
san
carlo
ca
briefli
mice
purchas
jackson
laboratori
sacramento
ca
bred
bsri
breeder
pair
hous
specificpathogen
free
condit
microisol
cage
innov
inc
san
diego
ca
mice
check
daili
date
litter
first
observ
consid
day
day
litter
mother
transfer
static
dispos
cage
innov
inc
transfer
facil
infect
treatment
neonat
mice
infect
pfu
chikv
strain
intraderm
ventral
thorax
mice
also
intraperiton
inject
control
human
iggmous
ml
phosphatebuff
salin
pb
immedi
prior
chikv
infect
control
igg
use
experi
purifi
igg
human
serum
sigmaaldrich
result
analyz
use
kaplanmei
surviv
curv
use
aabl
version
softwar
gigawiz
ltd
co
ok
signific
differ
determin
use
logrank
chisquar
analysi
result
adjust
multipl
comparison
result
consid
signific
p
antichikv
human
monoclon
antibodi
isol
ebv
transform
b
cell
chikv
infect
recov
individu
identifi
outbreak
chikv
northern
itali
chikv
pseudoviru
neutral
use
primari
screen
assay
select
b
cell
clone
heavi
light
chain
subsequ
sequenc
clone
separ
fab
fragment
isol
phage
display
librari
construct
multipl
chikv
infect
recov
individu
epidem
la
describ
materi
method
viruslik
particl
vlp
bind
assay
use
vlp
produc
chikv
capsid
envelop
env
glycoprotein
express
use
primari
screen
pan
phage
follow
use
chikv
pseudoviru
hivbackbon
base
without
chikv
capsid
neutral
assay
downstream
character
subsequ
antibodi
heavi
light
chain
sequenc
clone
human
full
length
igg
vector
protein
product
evalu
test
neutral
assay
perform
hek
cell
use
chikv
pseudovirus
bear
envelop
prototyp
west
african
asian
eastcentr
south
african
ecsa
chikv
strain
igg
antibodi
neutral
chikv
pseudovirus
approxim
mgml
mgml
ic
respect
figur
pseudoparticl
produc
use
envelop
deriv
strain
la
reunion
outbreak
similarli
sensit
neutral
ic
valu
mgml
mgml
respect
figur
similar
neutral
observ
regardless
cell
type
use
data
shown
neutral
specif
chikv
bind
antichikv
antibodi
intact
chikv
vlp
detect
use
fotebio
octetr
biosensor
mab
nm
bind
chikv
vlp
nonparticl
surfac
control
use
show
bind
specif
mab
intact
chikv
vlp
b
dose
respons
curv
bind
intact
chikv
vlp
raw
data
curv
antibodi
associ
dissoci
captur
chikv
vlp
shown
black
fit
curv
shown
red
data
fit
bind
model
determin
associ
rate
k
dissoci
rate
k
equilibrium
bind
affin
k
calcul
bind
chikv
vlp
nm
appar
affin
detect
crossreact
pseudovirus
express
alphaviru
envelop
rrv
sfv
sinv
well
vsvg
figur
mab
also
neutral
chikv
envelop
natur
occur
mutat
critic
site
near
fusion
loop
associ
increas
chikv
infect
transmiss
mosquito
vector
aed
albopictu
ic
mgml
ic
mgml
figur
test
replic
compet
chikv
plaqu
reduct
neutral
test
prnt
use
strain
exhibit
valu
approxim
mgml
compar
level
neutral
also
observ
strain
contrast
weak
neutral
observ
chikv
pseudoviru
assay
figur
fail
neutral
replic
compet
chikv
even
concentr
mgml
similarli
littl
inhibit
note
util
vesicular
stomat
virusbas
pseudotyp
rather
hivbas
cellcel
fusion
assay
maintain
similar
neutral
inhibitori
activ
data
shown
base
find
categor
strongli
neutral
antibodi
similar
potenc
human
mab
nonneutr
weakli
neutral
antibodi
live
viru
order
determin
strongli
mab
interact
nativ
virion
intact
chikv
vlp
captur
onto
surfac
fortebio
octet
red
biosensor
tip
fortebio
menlo
park
ca
antibodi
bind
immobil
particl
measur
use
biolay
interferometri
fortebio
menlo
park
ca
wherea
bound
vlp
appar
affin
nm
figur
b
fail
recogn
chikv
envelop
protein
intact
vlp
data
shown
suggest
epitop
may
occlud
nativ
conform
virion
find
consist
inabl
neutral
live
chikv
antibodi
recogn
envelop
deriv
chikv
vlp
semin
condit
protein
run
sdspage
gel
without
reduc
agent
suggest
recogn
conform
specif
epitop
depend
disulfid
bond
figur
chikv
envelop
protein
immunostain
antibodi
clone
reactiv
rel
wildtyp
chikv
env
identifi
critic
bind
mutat
six
individu
residu
alanin
significantli
reduc
bind
red
bar
affect
bind
green
bar
control
antibodi
gray
bar
residu
number
accord
pdb
entri
b
critic
bind
residu
shown
green
visual
chikv
env
crystal
structur
envelop
protein
subunit
monom
pdb
entri
depict
yellow
red
blue
respect
fusion
loop
shown
silver
left
panel
sideview
topdown
trimer
represent
center
right
panel
pdb
entri
structur
side
view
trimer
represent
center
panel
viral
membran
posit
bottom
figur
mab
epitop
map
use
shotgun
mutagenesi
order
identifi
residu
bind
epitop
mab
screen
comprehens
chikv
mutat
librari
nearli
everi
residu
within
envelop
subunit
encompass
aminoacid
residu
coverag
individu
mutat
alanin
alanin
mutat
serin
clone
express
cell
assess
antibodi
bind
use
immunofluoresc
stain
mean
fluoresc
determin
highthroughput
flow
cytometri
antibodi
reactiv
mutant
calcul
rel
reactiv
wildtyp
wt
chikv
env
clone
identifi
critic
bind
low
reactiv
high
reactiv
chikv
control
antibodi
rabbit
polyclon
antibodi
describ
materi
method
counterscreen
strategi
facilit
exclus
env
mutant
global
local
misfold
express
defect
residu
identifi
way
energet
critic
contributor
epitop
socal
hotspot
mab
bind
six
amino
acid
cluster
within
domain
identifi
critic
bind
residu
mutat
alanin
react
less
wt
reactiv
screen
high
reactiv
compar
three
antibodi
rabbit
polyclon
antibodi
suggest
mutant
envelop
protein
express
properli
fold
figur
epitop
appear
partial
occlud
visual
nativ
trimer
structur
figur
like
account
poor
neutral
exhibit
similar
epitop
map
studi
use
shotgun
mutagenesi
alanin
scan
identifi
residu
locat
bconnector
region
domain
b
chikv
chikv
envelop
protein
immunostain
antibodi
clone
reactiv
rel
wildtyp
chikv
env
identifi
critic
bind
mutat
residu
serin
significantli
reduc
bind
green
bar
affect
bind
red
bar
control
antibodi
gray
bar
residu
number
accord
pdb
entri
b
pseudovirus
test
inhibitori
potenc
infect
mutant
compar
wt
test
inset
graph
indic
mutant
hinder
chikv
env
fold
function
averag
raw
luminesc
unit
shown
construct
envminu
neg
control
c
critic
residu
shown
green
visual
chikv
env
crystal
structur
env
protein
subunit
monom
pdb
entri
depict
yellow
red
blue
respect
fusion
loop
shown
silver
left
panel
sideview
topdown
trimer
represent
center
right
panel
pdb
entri
structur
side
view
trimer
represent
center
panel
viral
membran
posit
bottom
figur
critic
residu
requir
recognit
figur
residu
solvent
expos
predict
easili
access
chikv
env
nativ
trimer
conform
figur
residu
acidsensit
region
asr
sandwich
critic
pocket
chikv
determin
chikv
envelop
crystal
structur
interestingli
asr
along
domain
b
also
recent
describ
alphavirus
unstructur
follow
acid
ph
trigger
studi
found
residu
mutat
serin
react
wt
reactiv
react
greater
wt
reactiv
antichikv
antibodi
strongli
suggest
mutant
properli
fold
involv
bind
interact
figur
residu
also
like
involv
epitop
either
contribut
weakli
interact
individu
mutat
alanin
suffici
disrupt
mab
bind
detect
critic
use
pseudovirion
viru
entri
defect
observ
indic
mutant
envelop
properli
fold
confirm
import
residu
bind
infect
experi
conduct
wild
type
mutant
pseudovirion
pseudovirion
ineffici
neutral
increas
ic
demonstr
residu
requir
potent
inhibit
figur
contrast
wild
type
natur
occur
variant
remain
fulli
sensit
assess
potenti
protect
activ
mab
vivo
use
adult
week
old
wildtyp
mous
model
chikv
diseas
mice
receiv
intraperiton
inject
purifi
igg
mgmous
approxim
mgkg
day
infect
reunion
island
isol
chikv
control
monoclon
antibodi
recogn
chikv
produc
fashion
pb
use
neg
control
infect
mice
monitor
viremia
foot
swell
describ
previous
control
group
chikv
infect
old
mice
result
day
viremia
increas
foot
swell
similar
describ
previous
control
anim
contrast
experi
week
old
mice
inject
igg
hour
prior
exposur
viru
show
detect
viremia
foot
swell
figur
result
demonstr
antibodi
complet
protect
adult
anim
prophylact
viremia
arthrit
diseas
order
evalu
therapeut
potenti
mab
inocul
neonat
mice
pfu
chikv
monitor
surviv
rate
mice
infect
chikv
surviv
day
mice
given
control
human
igg
surviv
day
figur
tabl
contrast
neonat
mice
inject
mg
mgkg
coincid
infect
surviv
p
compar
viru
alon
human
igg
also
observ
mgmous
mgkg
administ
therapeut
hour
hour
chikv
challeng
complet
protect
mice
tabl
therefor
potent
neutral
antibodi
therapeut
protect
wildtyp
neonat
mice
lethal
dose
viru
hour
post
chikv
inocul
protect
wildtyp
mice
viru
infect
vivo
monoclon
neutral
antibodi
thought
requir
close
ic
level
antibodi
serum
howev
littl
known
chikungunya
protect
mice
human
antichikv
mab
perform
vivo
antibodi
titrat
experi
dose
neonat
immedi
chikv
challeng
via
intraperiton
inject
mab
mgmous
approxim
equal
mgkg
respect
mice
fulli
protect
littl
mgkg
mab
mice
surviv
receiv
mgkg
mab
concurr
viral
challeng
figur
mice
given
mgkg
mab
succumb
chikvdriven
lethal
similarli
control
group
result
demonstr
potent
neutral
antibodi
ic
mgml
protect
mice
mgkg
mab
half
neonat
mice
mgkg
studi
describ
isol
character
two
human
monoclon
antibodi
chikv
infect
recov
individu
previous
develop
chikv
pseudoviru
assay
found
amen
current
studi
highthroughput
screen
select
bcell
clone
express
chikv
neutral
antibodi
neutral
chikv
pseudovirus
replicationcompet
virus
high
potenc
monoclon
antibodi
show
less
dramat
neutral
pseudoviru
neutral
live
viru
highest
concentr
test
mgml
suggest
although
chikv
antibodi
select
carri
use
highthroughput
pseudoviru
assay
greater
conveni
live
virusprnt
assay
reliabl
confirmatori
assay
chikv
neutral
also
report
develop
novel
comprehens
chikv
envelop
sitedirect
mutat
librari
nearli
residu
fulllength
chikv
envelop
protein
individu
mutat
alanin
order
identifi
critic
amino
acid
recogn
human
mab
recogn
spatial
proxim
residu
domain
howev
nonneutr
natur
antibodi
suggest
residu
easili
access
nativ
chikv
envelop
live
viru
inde
epitop
appear
partial
occlud
visual
nativ
trimer
crystal
structur
sitedirect
mutagenesi
map
studi
confirm
neutral
escap
mutant
studi
reveal
critic
mice
infect
chikv
hour
data
chikv
infect
mice
without
antibodi
treatment
mice
treat
control
antibodi
hour
also
shown
figur
residu
requir
mab
recognit
interestingli
base
crystal
structur
chikv
envelop
residu
locat
asr
encompass
amino
acid
asr
along
domain
b
highli
conserv
function
region
among
alphavirus
involv
conform
rearrang
trigger
acid
ph
lead
exposur
fusion
loop
final
result
membran
fusion
possibl
neutral
antibodi
bind
asr
region
could
fulli
partial
prevent
disord
dissoci
follow
ph
trigger
therebi
reduc
fusion
effici
chikv
entri
residu
within
asr
previous
report
critic
effici
particl
format
stabil
highlight
delic
conform
balanc
region
bring
critic
residu
highli
conserv
among
differ
chikv
strain
repres
west
african
isol
well
recent
circul
strain
howev
previou
studi
describ
strain
isol
uganda
outbreak
valin
posit
mutat
valin
result
loss
potenc
suggest
activ
current
circul
strain
chikv
strain
aris
futur
particular
aminoacid
fact
protein
bear
aliphat
hydrophob
aminoacid
alanin
valin
prevent
neutral
polar
serin
residu
posit
escap
neutral
suggest
form
critic
hydrophob
interact
sidechain
posit
neutral
antibodi
shown
critic
recoveri
alphaviru
infect
number
neutral
epitop
character
albeit
hand
chikv
particular
note
antibodi
specif
sinv
previous
document
escap
mutant
posit
equival
chikv
residu
asr
sinv
glycoprotein
isol
character
addit
chikv
mab
offer
insight
proport
antibodi
elicit
particular
epitop
chikv
infect
individu
time
appear
exampl
eleg
studi
recent
describ
predomin
proport
earli
respons
chikv
envelop
compos
antibodi
direct
ntermin
sequenc
littl
known
concern
chikungunya
protect
human
monoclon
antibodi
order
elucid
whether
strong
vitro
neutral
would
translat
protect
vivo
use
antibodi
adult
wildtyp
mous
model
chikv
diseas
contrast
control
mice
mice
pretreat
antibodi
detect
chikv
viremia
arthriti
previou
studi
human
igg
purifi
pool
plasma
chikv
recov
individu
titrat
pathogen
neonat
mous
model
chikungunya
similar
one
model
use
current
studi
shown
fulli
protect
present
concentr
mg
per
mous
anoth
recent
studi
describ
two
monoclon
antibodi
protect
vivo
ifndefici
mice
two
antibodi
protect
mice
mgkg
mg
per
mous
howev
antibodi
fail
protect
mice
mgkg
mg
per
mous
abl
delay
chikvdriven
lethal
vivo
antibodi
titrat
experi
describ
demonstr
mice
protect
mgkg
mab
vitro
ic
mgml
mice
protect
mgkg
data
consist
determin
vivo
protect
viral
infect
neutral
antibodi
mgkg
could
also
protect
half
anim
chikvdriven
lethal
order
evalu
therapeut
potenti
mab
inocul
wildtyp
neonat
mice
robust
dose
chikv
pfu
monitor
surviv
rate
observ
mab
mgmous
administ
therapeut
hour
chikv
infect
complet
protect
mice
report
demonstr
prophylact
therapeut
protect
viremia
vivo
neutral
antibodi
target
acidsensit
region
chikv
although
passiv
antibodi
like
would
util
protect
chikv
regular
basi
one
envisag
scenario
potent
antibodi
like
manufactur
use
protect
highli
suscept
individu
pregnant
women
infant
older
individu
chikv
epidem
protect
travel
militari
inadvert
expos
viru
isol
epitop
character
antibodi
demonstr
potent
neutral
vitro
vivo
invalu
futur
studi
aim
identif
neutral
epitop
order
produc
effect
antigen
vaccin
hypothes
epitop
recogn
antibodi
also
import
region
target
antibodybas
intervent
futur
antichikv
strategi
recent
studi
demonstr
use
combin
mab
advantag
vivo
protect
limit
develop
resist
differ
mechan
viral
spread
given
direct
region
chikv
target
mab
particularli
use
partner
combin
figur
human
mab
neutral
neutral
pseudoviru
bear
chikv
strain
orang
line
chikv
strain
green
line
vsvg
control
magenta
line
envelop
b
mab
antibodi
concentr
shown
xaxi
result
express
percentag
antibodi
control
repres
mean
triplic
well
repres
three
experi
tiff
figur
western
blot
reduc
nonreduc
chikv
vlp
use
mab
antibodi
ugml
test
reactiv
ug
chikv
vlp
treat
dttheat
hrp
signal
detect
use
luminesc
ad
ratio
femto
supersign
tiff
text
support
method
docx
